Home » Stocks » DRIO

DarioHealth Corp. (DRIO)

Stock Price: $22.41 USD 0.42 (1.91%)
Updated Jan 25, 2021 2:08 PM EST - Market open
Market Cap 202.50M
Revenue (ttm) 7.29M
Net Income (ttm) -30.77M
Shares Out 7.33M
EPS (ttm) -7.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $22.41
Previous Close $21.99
Change ($) 0.42
Change (%) 1.91%
Day's Open 22.50
Day's Range 21.39 - 23.95
Day's Volume 173,662
52-Week Range 3.50 - 23.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of DarioHealth Corp. (Nasdaq: DRIO) concerning the Company and its directors' and officers'...

PRNewsWire - 1 month ago

NEW YORK, Dec. 22, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the Company has entered into an agreem...

Seeking Alpha - 2 months ago

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter 2020 and p...

Seeking Alpha - 3 months ago

DRIO offers a diabetes management solution that is highly rated, provides strong ROI for all parties, and simpler than main competitor Livongo. Seasoned executives in the digital therapeutics ...

PRNewsWire - 3 months ago

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that Vitality Group has chosen the company's digital th...

Seeking Alpha - 5 months ago

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of DarioHealth (NASDAQ:DRIO) moved higher by 2% in pre-market trading after the company reported Q2 results.

PRNewsWire - 5 months ago

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- DarioHealth Corp.

PRNewsWire - 5 months ago

NEW YORK, July 31, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it closed a private placement transaction wi...

PRNewsWire - 7 months ago

NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote ...

Seeking Alpha - 8 months ago

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of DarioHealth (NASDAQ:DRIO) remained unaffected at $7.95 after the company reported Q1 results.

Seeking Alpha - 10 months ago

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Shares of digital health company DarioHealth Corp (NASDAQ: DRIO) are advancing strongly Tuesday.

Market Watch - 1 year ago

Shares of DarioHealth Corp. DRIO, +23.40% jumped 103% as it announced that Walmart would sell DarioHealth's digital diabetes management system online.

Seeking Alpha - 1 year ago

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

DarioHealth's (DRIO) CEO Erez Raphael on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

DarioHealth's (DRIO) CEO Erez Raphael on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2018 Results - Earnings Call Transcript

About DRIO

DarioHealth, a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring devi... [Read more...]

Industry
Diagnostics & Research
Founded
2011
CEO
Erez Raphael
Employees
62
Stock Exchange
NASDAQ
Ticker Symbol
DRIO
Full Company Profile

Financial Performance

In 2019, DarioHealth's revenue was $7.56 million, an increase of 2.23% compared to the previous year's $7.39 million. Losses were -$17.74 million, -0.38% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DarioHealth stock is "Strong Buy." The 12-month stock price forecast is 16.32, which is a decrease of -27.18% from the latest price.

Price Target
$16.32
(-27.18% downside)
Analyst Consensus: Strong Buy